Reduced N-Acetylaspartate to Creatine Ratio in the Posterior Cingulate Correlates with Cognition in Alzheimer's Disease following Four Months of Rivastigmine Treatment
Reduced N-Acetylaspartate to Creatine Ratio in the Posterior Cingulate Correlates with Cognition in Alzheimer's Disease following Four Months of Rivastigmine Treatment
复制标题
DOI：
10.1159/000367685
复制
发表时间：
2015-01-01
影响因子：
2.4
通讯作者：
Bartha, Robert
中科院分区：
文献类型：
--
作者：
Penner, Jacob;Wells, Jennie L.;Bartha, Robert
目的：确定4个月的利凡斯明治疗是否会导致阿尔茨海默病(AD)患者的代谢变化，以及代谢变化是否与认知变化相关。方法：在治疗前和治疗4个月后，对AD患者的后扣带回皮质进行磁共振成像扫描和认知功能测试。代谢物浓度被量化，并用于计算代谢物比率。结果：治疗4个月后，N-乙酰天冬氨酸/肌酸(NAA/Cr)比值平均下降12.7%，但NAA/Cr比值的变化与简明精神状态检查分数的变化呈正相关。结论：NAA/Cr值变化与认知功能变化呈正相关，提示NAA/Cr值可作为评价利凡斯明治疗反应的客观指标。(C)2014年S.Karger股份公司，巴塞尔。
Aim: To determine whether 4 months of rivastigmine treatment would result in metabolic changes and whether metabolic changes correlate with changes in cognition in people with Alzheimer's disease (AD). Methods: Magnetic resonance spectra were acquired from the posterior cingulate cortex of subjects with AD at 3 T. Magnetic resonance imaging scans and cognitive tests were performed before and 4 months after the beginning of the treatment. Metabolite concentrations were quantified and used to calculate the metabolite ratios. Results: On average, the N-acetylaspartate/creatine (NAA/Cr) ratio decreased by 12.7% following 4 months of rivastigmine treatment, but changes in the NAA/Cr ratio correlated positively with changes in Mini-Mental State Examination scores. Conclusion: This positive correlation between changes in NAA/Cr and changes in cognitive performance suggests that the NAA/Cr ratio could be an objective indicator of a response to rivastigmine treatment. (C) 2014 S. Karger AG, Basel.